Fondaparinux - data on efficacy and safety in special situations

Nagler, Michael; Haslauer, Michael; Wuillemin, Walter A (2012). Fondaparinux - data on efficacy and safety in special situations. Thrombosis research, 129(4), pp. 407-17. Amsterdam: Elsevier 10.1016/j.thromres.2011.10.037

Full text not available from this repository. (Request a copy)

New anticoagulants promise to have better efficacy, more safety and/or a better manageability than traditional anticoagulants. However, knowledge is limited regarding special situations such as renal insufficiency, obesity, pregnancy, long-term therapy, heparin-induced thrombocytopenia, treatment in patients with mechanical heart valves, use for children, and in patients with a high risk of thromboembolic complications. These situations have rarely or even never been the objective of randomised controlled trials. The purpose of the present article is to summarize and discuss available data on efficacy and safety in these special situations for one of the first new anticoagulants, the indirect factor-Xa inhibitor fondaparinux. Furthermore, we discuss safety in licensed indications and management of bleeding complications and comment on measuring of drug concentration in plasma.

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Nagler, Michael








Factscience Import

Date Deposited:

04 Oct 2013 14:28

Last Modified:

17 Mar 2015 21:12

Publisher DOI:


PubMed ID:


Web of Science ID:


URI: (FactScience: 216256)

Actions (login required)

Edit item Edit item
Provide Feedback